Several proactive videos made this statement. If these was funding issues in the background not made known to shareholders thats another story but was about timing and lack patients not lack of funding that was a basher theory. Funding issues are always a concern with any pre rev bio but when you hit pvalue for sub population and all you need to do is repeat same results i don’t think they would let funding slow this down.